Skip to content

The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation

A Prospective, Randomized Trial to Investigate the Effects of Glucose/ Ischemic Preconditioning Donor Pre-treatment on Reperfusion Injury in Deceased-Donor Liver Transplantation

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00718575
Enrollment
50
Registered
2008-07-18
Start date
2008-08-31
Completion date
2012-03-31
Last updated
2014-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Keywords

Liver Disease, Transplantation

Brief summary

Standard liver retrieval procedures for transplantation from a deceased donor inevitably result in a reperfusion injury to the liver tissue. The purpose of this research study is to find out whether treatment of the liver with a preconditioning protocol before its removal from the donor will help reduce any of this injury. The preconditioning treatment being tested has two components. Firstly, a solution of glucose+insulin is infused and secondly, blood flow to the liver is stopped briefly (10 minutes) and then resumed. Both strategies, individually, have been shown to reduce liver tissue injury in human studies. We hypothesize that combining both strategies will have a clinical benefit to patients and will improve liver function following transplant.

Detailed description

Liver transplantation is the only chance of cure for patients with end-stage liver disease. Unfortunately, standard organ preservation results in an ischemic-reperfusion injury (IRI) at the time of graft implantation. Novel strategies have been proposed to decrease reperfusion injury and improve graft function. This study will be the first to combine both strategies in a randomized, prospective trial. The intervention will occur during the retrieval surgery prior to cold preservation. Briefly, a glucose and insulin solution will be infused via the mesenteric vein at a controlled rate. Immediately prior to cross-clamping, blood supply to the liver will be restricted for 10 minutes and then resumed for 10 minutes before beginning cold preservation. All remaining surgical procedures, including the recipient surgery, will be performed by standard techniques. The liver recipient does not directly receive any intervention during this study.

Interventions

PROCEDUREGlucose/Ischemic Preconditioning Pre-treatment

A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Recipient 18 years of age or older * Recipient with chronic end-stage liver disease * Deceased donor liver transplant * Recipient capable of providing written informed consent * Whole organ graft from donors aged 60 years or older

Exclusion criteria

* Fulminant liver failure * Objection by any other member of the retrieval team * Split-liver grafts * Donor that has received total parenteral nutrition within 24hr of organ retrieval Donors from whom the pancreas and/or small bowel are also being retrieved

Design outcomes

Primary

MeasureTime frame
Reperfusion injury determined by peak ASTfirst 24 hours post-operative

Secondary

MeasureTime frame
Biliary Complications, infection and rejectionfirst month post-transplantation
graft and patient survival; length of hospital stay; length of ICU stay30 days and 90 days post-transplantation
Liver ATP and glycogen content; blood cytokine levels; liver gene expression of pro- and anti-apoptotic genesimmediately pre-removal and post- transplantation

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026